Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway
- PMID: 23307955
- PMCID: PMC3564450
- DOI: 10.1167/iovs.12-11291
Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway
Abstract
Purpose: Neovascularization (NV) is a sight-threatening complication of retinal ischemia in diabetes, retinal vein occlusion, and retinopathy of prematurity. Current treatment modalities, including laser photocoagulation and repeated intraocular injection of VEGF antagonists, are invasive and not always effective, and may carry side effects. We studied the use of hyperoxia as an alternative therapeutic strategy for regressing established vitreous NV in a mouse model of oxygen-induced ischemic retinopathy.
Methods: Hyperoxia treatment (HT, 75% oxygen) was initiated on postnatal day (P)17 after the onset of vitreous NV. Immunohistochemistry and quantitative PCR were used to assess retinal vascular changes in relation to apoptosis, and expression of VEGFR2 and inflammatory molecules. Effects of intravitreal injections of VEGF-A, VEGF-E, PlGF-1, and VEGF trap were also studied.
Results: HT selectively reduced NV by 70% within 24 hours. It robustly increased the level of cleaved caspase-3 in the vitreous NV between 6 and 18 hours and promoted infiltration of macrophage/microglial cells. The HT-induced apoptosis was preceded by a significant reduction in VEGFR2 expression within the NV and an increase in VEGFR2 within the surrounding neural tissue. Intravitreal VEGF-A and VEGF-E (VEGFR2 agonist) but not PlGF-1 (VEGFR1 agonist) prevented HT-induced apoptosis and regression of NV. In contrast, VEGF trap and VEGFR2 blockers mimicked the effect of HT. However, intravitreal VEGF trap induced increases in inflammatory molecules while HT did not have such unwanted effect.
Conclusions: HT may be clinically useful to specifically treat proliferative NV in ischemic retinopathy.
Conflict of interest statement
Disclosure:
Figures
Similar articles
-
Hyperoxia therapy of pre-proliferative ischemic retinopathy in a mouse model.Invest Ophthalmol Vis Sci. 2011 Aug 11;52(9):6384-95. doi: 10.1167/iovs.11-7666. Invest Ophthalmol Vis Sci. 2011. PMID: 21705685 Free PMC article.
-
Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog.Invest Ophthalmol Vis Sci. 2011 Jun 8;52(7):4039-47. doi: 10.1167/iovs.10-6798. Invest Ophthalmol Vis Sci. 2011. PMID: 21357392 Free PMC article.
-
Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA.Exp Eye Res. 2010 Sep;91(3):433-9. doi: 10.1016/j.exer.2010.06.019. Epub 2010 Jul 1. Exp Eye Res. 2010. PMID: 20599960
-
Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis).Trans Am Ophthalmol Soc. 2010 Dec;108:96-119. Trans Am Ophthalmol Soc. 2010. PMID: 21212851 Free PMC article. Review.
-
Sensitivity of different vascular beds in the eye to neovascularization and blood-retinal barrier breakdown in VEGF transgenic mice.Adv Exp Med Biol. 2000;476:129-38. doi: 10.1007/978-1-4615-4221-6_11. Adv Exp Med Biol. 2000. PMID: 10949661 Review.
Cited by
-
Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy.Eye Brain. 2016 May 20;8:81-90. doi: 10.2147/EB.S94449. eCollection 2016. Eye Brain. 2016. PMID: 28539803 Free PMC article. Review.
-
Potential biomarkers for retinopathy of prematurity identified by circular RNA profiling in peripheral blood mononuclear cells.Front Immunol. 2022 Aug 23;13:953812. doi: 10.3389/fimmu.2022.953812. eCollection 2022. Front Immunol. 2022. PMID: 36081509 Free PMC article.
-
Therapeutic Effect of Traditional Chinese Medicine on a Rat Model of Branch Retinal Vein Occlusion.J Ophthalmol. 2019 Feb 18;2019:9521379. doi: 10.1155/2019/9521379. eCollection 2019. J Ophthalmol. 2019. PMID: 30906588 Free PMC article.
-
A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.PLoS One. 2015 Jun 17;10(6):e0129383. doi: 10.1371/journal.pone.0129383. eCollection 2015. PLoS One. 2015. PMID: 26083024 Free PMC article. Review.
-
Epac1 inhibition ameliorates pathological angiogenesis through coordinated activation of Notch and suppression of VEGF signaling.Sci Adv. 2020 Jan 1;6(1):eaay3566. doi: 10.1126/sciadv.aay3566. eCollection 2020 Jan. Sci Adv. 2020. PMID: 31911948 Free PMC article.
References
-
- Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina. 2007; 27: 816–824 - PubMed
-
- Tolentino MJ. Current molecular understanding and future treatment strategies for pathologic ocular neovascularization. Curr Mol Med. 2009; 9: 973–981 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials